Trial Profile
Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM).
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 23 Dec 2011 Primary endpoint identified as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.